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Levels of amyloid-beta monomer and deposited
amyloid-beta in the Alzheimer’s disease brain are orders
of magnitude greater than soluble amyloid-beta oligomer
levels. Monomeric amyloid-beta has no known direct
toxicity. Insoluble fibrillar amyloid-beta has been
proposed to be an in vivo mechanism for removal
of soluble amyloid-beta and exhibits relatively low
toxicity. In contrast, soluble amyloid-beta oligomers are
widely reported to be the most toxic amyloid-beta form,
both causing acute synaptotoxicity and inducing
neurodegenerative processes. None of the amyloid-beta
immunotherapies currently in clinical development
selectively target soluble amyloid-beta oligomers, and
their lack of efficacy is not unexpected considering
their selectivity for monomeric or fibrillar amyloid-beta
(or both) rather than soluble amyloid-beta oligomers.
Because they exhibit acute, memory-compromising
synaptic toxicity and induce chronic neurodegenerative
toxicity and because they exist at very low in vivo levels
in the Alzheimer’s disease brain, soluble amyloid-beta
oligomers constitute an optimal immunotherapeutic
target that should be pursued more aggressively.implications for current Aβ immunotherapies and newIntroduction
Alzheimer’s disease (AD) is the most common form of de-
mentia, accounting for 60% to 80% of all dementias [1,2].
Worldwide, the prevalence of dementia was more than 35
million in 2010, and projections exceed 65 million by
2030 and 115 million by 2050 [1]. Significantly, no drugs
that prevent or slow the progression of AD are currently
approved. The development of effective AD therapeutics
is clearly a tremendous medical challenge and should be
one of society’s top medical priorities.* Correspondence: wgoure@acumenpharm.com
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2014Despite the great need and significant societal and finan-
cial incentives, many pharmaceutical companies and in-
vestors have reduced investments in the search for new
AD drugs, citing recent clinical failures of several high-
profile experimental AD therapeutics and the high risks
and costs of such development endeavors. The recent
clinical failures also have intensified scrutiny of the ‘amyl-
oid cascade hypothesis’, which spawned many of the recent
experimental AD drugs targeting the amyloid-beta (Aβ)
peptide. Nevertheless, the causal linkage between Aβ and
AD remains strong and is supported by hundreds of stud-
ies over the past two decades [3-10]. (This is a representa-
tive sample of published reviews, and apologies are given
to the authors of many excellent reviews that are not
cited.)
Essentially all Aβ therapeutic approaches so far have
targeted reducing the levels of Aβ monomer or Aβ de-
posits (or both) in the brain. However, today, the causal
role of Aβ in AD is widely considered to involve soluble
Aβ oligomers, and therapeutic strategies that selectively
target soluble Aβ oligomers offer the potential to deliver
rapid symptomatic benefit and long-term disease modifi-
cation. This review describes the role of soluble Aβ olig-
omers within the amyloid hypothesis and discusses
immunotherapies directed selectively toward soluble Aβ
oligomers.The amyloid cascade hypothesis
The first suggestion of an ‘amyloid hypothesis’ to explain
the pathology of AD was that of Wong and colleagues
[11], who postulated that Aβ-derived cerebrovascular
amyloid caused seepage of Aβ and other substances
from plasma into the brain, leading to the formation of
Aβ plaques and possibly neurodegeneration. This was
revised into the more well-known amyloid cascade hy-
pothesis that proposed that deposition of Aβ as neuritic
plaques caused AD and led to neurofibrillary tangles, celltd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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hypothesis linking Aβ to AD catalyzed much of AD and
Aβ research over the past two decades, and key studies
during that period led to important revisions of the hy-
pothesis that highlighted the central role of soluble Aβ
oligomers in synaptic dysfunction and loss [4,13-19].
The current understanding of the Aβ cascade is derived
primarily from in vitro studies, the vast majority of which
were conducted by using Aβ concentrations orders of
magnitude greater than those found in vivo. The assembly
of Aβ peptides to form soluble oligomers, protofibrils, and
fibrils is well documented to be affected by the isoform of
the starting peptide, how the peptide is treated prior to
assembly, the nature of the buffer, pH, peptide concentra-
tion, assembly temperature and time, agitation, and pres-
ence of other peptides or biological materials [20-24].
Moreover, preparations of soluble Aβ species have been
shown to change with time or upon dilution in different
buffers, particularly in cell culture media [19]. Thus, cau-
tion must be taken in extrapolating the results and con-
clusions of in vitro studies to in vivo reality. Although
precise mechanistic details remain to be elucidated, a
multitude of studies by numerous researchers support the
conclusion that monomeric Aβ peptides assemble to form
soluble Aβ oligomers, which further aggregate to form
fibrillar Aβ [17,25].
Three distinct pools of Aβ species exist: Aβ monomers,
soluble Aβ oligomers, and insoluble fibrillar Aβ. Each of
these pools encompasses an array of individual species.
Thus, monomeric Aβ peptides encompass various iso-
forms, including Aβ(1-40), Aβ(1-42), and Aβ(1-43), as well
as numerous N-terminal truncated isoforms. (For ex-
ample, see the introductory paragraphs of Tekirian and
colleagues [26].) Insoluble fibrillar Aβ aggregates are also
known to be heterogeneous in structure and composed
of various Aβ isoforms, both full-length as well as
N-terminal and C-terminal truncated isoforms. (For ex-
ample, see the introductory paragraphs of Roher and col-
leagues [27] and Thal and colleagues [28].)
Soluble Aβ oligomers are also heterogeneous and per-
haps more ambiguous because of the different termin-
ologies used by different researchers to describe them.
(For an excellent review of soluble Aβ oligomers, see
Benilova and colleagues [9].) Thus, soluble Aβ oligomer
species reported by various researchers have been
termed sodium dodecyl sulfate (SDS)-stable Aβ oligo-
mers [29,30], low-n-oligomers [31-33], dimers [33-35],
trimers [33,36-38], tetramers [37], paranuclei [38,39],
dodecamers and Aβ*56 [37,40,41], amyloid-derived dif-
fusible ligands (ADDLs) [42-44], Aβ oligomers [45], pre-
fibrillar oligomers [46], Aβ globulomers [40,47-49],
spherical oligomers [50], amylospheroids [51,52], proto-
fibrils [20,53,54], and annular protofibrils [55,56]. Most
of these terminologies refer to a mixture of metastable,soluble Aβ oligomer species in equilibrium rather than a
discrete, stable species. In many cases, there is similarity
in the species comprising the different preparations. In
this review, we will use the terminology soluble Aβ olig-
omers to describe Aβ species composed of more than
one Aβ peptide that remain in solution following centri-
fugation. Aβ fibrils or fibrillar Aβ will be used as a gen-
eral description of insoluble Aβ plaques and vascular
amyloid. (The term Aβ plaques rather than amyloid pla-
ques will be used to more precisely describe amyloid
plaques comprising primarily Aβ peptides versus those
comprising primarily non-Aβ peptides.)
It has been established that the levels of Aβ monomer
and deposited fibrillar Aβ in the AD brain are orders of
magnitude greater than soluble Aβ oligomer levels
[57-65]. However, more than three decades of intense in-
vestigation has not provided a precise understanding of
the extent of interconversion among the various Aβ
species.
Aβ dimers have been demonstrated to form at physiolo-
gically relevant concentrations of Aβ monomer in vivo
[66,67]. Numerous in vitro studies have shown that sol-
uble Aβ oligomers and protofibrils form under similar
conditions and that both species can proceed to form lar-
ger fibrillar species [20,43,53,68-74]. More recent studies
provide further support for the addition of soluble Aβ
oligomers to protofibrillar and fibrillar assemblies and also
provide data indicating that oligomerization can occur via
a secondary nucleation mechanism caused by fibrillar Aβ
[73,74], possibly suggesting a mechanistic linkage between
fibrillar Aβ and soluble Aβ oligomers. However, the pre-
cise mechanism of in vivo fibril formation has not been
fully established.
Aβ plaques are now generally considered to be a rela-
tively benign species [19,72,75]; however, whether Aβ pla-
ques are a sink or a source for toxic soluble Aβ oligomers
is a subject of debate. Several studies with γ-secretase inhib-
itors [76-79] and two studies in transgenic mice that over-
express mutant amyloid precursor protein (APP) via a
doxycycline-regulated promoter [80,81] show that sub-
chronic or chronic suppression of Aβ production arrested
Aβ plaque formation but did not result in observable clear-
ance of existing plaques. In a related study [82], Aβ(1-42)
immunization of Tg2576 mice prior to significant Aβ de-
position, at an age with modest deposition or at an age with
significant deposition, showed that immunization prevented
additional Aβ deposition but did not result in significant
clearance of pre-existing Aβ. These studies indicate that
mature, dense-core Aβ plaques are not in significant equi-
librium with soluble Aβ pools. Studies in transgenic mouse
models of AD reporting decreased soluble Aβ oligomer
levels and reduced cognitive deficits with increasing Aβ
plaque levels also provide support for the concept that Aβ
plaques may be a sink for soluble Aβ species [83,84].
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using a novel microdialysis technique, the half-life of low-
molecular-weight Aβ species in hippocampal interstitial
fluid following inhibition of Aβ production by a potent
secretase inhibitor was doubled in 12- to 15-month-old
mice with Aβ deposits compared with 3-month-old mice
without Aβ deposits [85]. On the basis of these results, it
was suggested that insoluble Aβ was in equilibrium
with soluble Aβ in the interstitial fluid. In a related
study using similar techniques, the temporal changes of
low-molecular-weight Aβ species in interstitial fluid and
Aβ levels in Tris-buffered saline (TBS), SDS, and formic
acid extracts of brain tissues of 3-, 12-, and 24-month-old
APP transgenic mice were reported [86]. A significant
age-dependent decrease in low-molecular-weight Aβ in
interstitial fluid and significant increases in Aβ species in
SDS and formic acid extracts of brain tissues were found.
Although Aβ increased approximately seven-fold from
baseline in the TBS extract of brain tissues, the level of Aβ
in TBS extracts was less than 2% of the total Aβ in SDS
and formic acid extracts. These results indicated an age-
dependent sequestration of Aβ as non-diffusible cell
matrix and membrane-bound Aβ and deposited Aβ pla-
ques. Acute γ-secretase inhibition of Aβ production in
plaque-free and plaque-rich mice suggested that Aβ(1-42)
in the interstitial fluid of plaque-rich mice was derived pri-
marily from Aβ(1-42) sequestered in brain parenchyma
rather than from new biosynthesis. However, it was not
possible to determine whether cell matrix and membrane-
bound Aβ or Aβ plaques or both forms of Aβ were the
source of Aβ(1-42) in the interstitial fluid of aged mice.
In a more recent study of the temporal changes of Aβ
species in the interstitial fluid and brain tissues of APP
transgenic mice, Takeda and colleagues [87], using a
1,000-kDa-molecular-weight cutoff microdialysis probe,
reported the temporal changes in soluble Aβ oligomer
levels. In that study, consistent with previous studies
[85,86], a significant, age-dependent increase in Aβ levels
in TBS and formic acid extracts of brain tissues was
found, and TBS extractable Aβ was less than 1% of formic
acid extractable Aβ. However, unlike previous studies
using a 35-kDa-molecular-weight cutoff microdialysis
probe [85,86], a significant, age-dependent increase in
interstitial fluid Aβ levels was found by using the larger-
pore-sized microdialysis probe. The majority of the Aβ in
interstitial fluid was determined to be higher-molecular-
weight soluble Aβ oligomers, which showed an age-
dependent increase relative to lower-molecular-weight Aβ
species. Temporal changes in soluble Aβ oligomer levels
in interstitial fluid and TBS brain extracts showed a sig-
nificant positive correlation with formic acid Aβ extract
levels. Comparison of high- and low-molecular-weight
interstitial fluid Aβ levels at baseline and following acute
treatment with a γ-secretase inhibitor showed slowerclearance of higher-molecular-weight Aβ oligomers com-
pared with low-molecular-weight Aβ species.
Narayan and colleagues [88] have recently used single-
molecule imaging techniques to investigate interactions be-
tween Aβ peptides and hippocampal cell membranes and
reported results indicating that Aβ oligomers preferentially
interact with membranes compared with Aβ monomer,
thereby providing support for the results observed in the
microdialysis studies. Thus, this study, coupled with those
of the temporal changes of Aβ species in APP transgenic
mice [85-87], does not resolve the controversy regarding
the sink/source relationship between fibrillar and soluble
Aβ species.
The sink/source relationship between soluble and insol-
uble Aβ pools is complex, not fully understood, and sub-
ject to ongoing debate. Two different forms of Aβ plaques
are present in the AD brain: vascular amyloid plaques that
are primarily composed of Aβ(1-40) and Aβ plaques that
are primarily composed of Aβ(1-42) [89]. In vitro studies
have shown that fibrillar Aβ(1-40) and Aβ(1-42) are in
equilibrium with soluble Aβ [90,91] but that recycling of
Aβ(1-40) fibrils is significantly faster that Aβ(1-42) fibrils
[91]. Moreover, it has been reported that plaque depos-
ition proceeds in two distinct kinetic phases: an initial, re-
versible deposition phase followed by a time-dependent
irreversible deposition phase [92]. Furthermore, a recent
study of the rates of formation of Aβ oligomers and fibrils
provided evidence that the formation of soluble Aβ oligo-
mers from monomeric Aβ is catalyzed by fibrillar Aβ [73].
This study not only indicated a mechanistic linkage be-
tween soluble Aβ oligomers and fibrillar Aβ but also pro-
vided evidence showing that fibrillar Aβ can be a ‘source’ of
soluble Aβ via catalyzed oligomerization of Aβ monomer
rather than via a disaggregation process. This study also
provided an alternative explanation for the study by Koffie
and colleagues [93], who reported a halo of soluble Aβ olig-
omers surrounding Aβ plaques and proposed that Aβ pla-
ques were a possible source of soluble Aβ oligomers.
Although precise details remain to be fully elucidated,
collectively, over two decades of studies on the mecha-
nisms of formation of oligomeric and fibrillar Aβ, the
temporal distribution of Aβ species in vitro and in vivo,
the age-dependent effect of Aβ immunization, and the
effects of subchronic and chronic suppression of Aβ pro-
duction upon in vivo Aβ plaque levels show a significant,
age-dependent increase in brain levels of soluble Aβ
oligomers and deposited fibrillar Aβ. Collectively, the
studies suggest that mature, dense-core Aβ plaques are
not in equilibrium to any significant extent with soluble
pools of Aβ, but that Aβ sequestered in the cell matrix
and membranes and immature plaques is in equilibrium
with soluble Aβ pools, and that fibrillar Aβ catalyzes Aβ
monomer oligomerization, giving rise to soluble Aβ olig-
omers and growth of Aβ plaques.
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Monomeric Aβ, primarily the Aβ(1-40) and Aβ(1-42)
peptides, is produced in various cell types throughout
the body and reported to have trophic properties in vitro
[94,95]. There are no reports suggesting that monomeric
Aβ possesses any direct cellular toxicity at physiologic-
ally relevant concentrations. Insoluble fibrillar aggregates
of Aβ, vascular amyloid and Aβ plaques, exhibit rela-
tively low in vitro toxicity and have been proposed to be
an in vivo mechanism for removal of the more toxic sol-
uble Aβ species [83,96,97]. It was first suggested in 1995
that soluble Aβ species rather than fibrillar plaques
could trigger neurotoxicity leading to AD [98], and in
the subsequent decades, many studies have shown sol-
uble Aβ oligomers to be the most toxic Aβ form, causing
both acute synaptotoxicity and inducing neurodegenera-
tive processes [5-10,99-102].
Low-picomolar levels of soluble Aβ oligomers have been
reported to have trophic properties in vitro [103-105], sug-
gesting that therapeutic targeting of soluble Aβ oligomers
may need to modulate oligomer levels versus completely
sequestering or preventing formation of soluble Aβ oligo-
mers. However, the concentration of Aβ42 at which en-
hancement of long-term potentiation (LTP) was observed
in these studies was one to two orders of magnitude
greater than levels of soluble Aβ oligomers reported in the
cerebrospinal fluid (CSF) of human patients with AD, and
the concentration above which inhibition of LTP was ob-
served was an order of magnitude greater than the total
levels of soluble Aβ species reported in the CSF of human
patients with AD [65]. Thus, the relevance of the reported
in vitro trophic properties of soluble Aβ oligomers to
in vivo conditions remains to be established.
Soluble Aβ oligomers bind with high affinity to synap-
ses on a subset of hippocampal and cortical neurons
[19,40,106-108], indicative of specific binding to discrete
cell surface receptors. In rodent hippocampal slice prep-
arations, synaptic binding leads to rapid inhibition of
LTP [19,40,109], and injection of various soluble Aβ
oligomer preparations directly into the rodent brain
leads to reversible impairment of cognitive function
[31,33,110]. This aberrant signaling also causes accumu-
lated biochemical damage within neurons [100,111,112],
such as hyperphosphorylation of tau [100,111-113], sug-
gesting a linkage between Aβ and tau pathologies
[114-116]. Soluble Aβ oligomers have been isolated from
extracts of postmortem AD brain tissue and from trans-
genic AD animal models [37,52,117-119] and have been
reported to be elevated in human AD brain relative to
non-demented older patients [59,61,62,65,119-124]. Im-
portantly, a recent study suggests a correlation between
CSF levels of soluble Aβ oligomers and cognitive deficits
in human patients with AD [61,65]. These findings sup-
port the view that soluble Aβ oligomers interfere acutelywith normal synaptic functions and contribute signifi-
cantly to the memory loss and cognitive dysfunction
characteristic of AD.
Structure and activity of soluble amyloid-beta
oligomer species
There is substantial ongoing debate and research con-
cerning the structure and activity of soluble Aβ species
[5,7-9,33,41,52,72,99,125-127]. Various soluble Aβ oligo-
mer species have been reported to display synaptic tox-
icity or induce cognitive deficits, including dimers
[33,35,128,129], trimers [32], dodecamers [33,37,40], and
larger soluble Aβ oligomers with molecular weights of
90 to 650 kDa (20 to 150 mers) [19,130,131]. Unfortu-
nately, the different methodologies for the preparation,
characterization, and evaluation of soluble Aβ oligomer
species by various research groups impede a direct com-
parison of the results reported, and few studies have dir-
ectly compared the toxicities of different soluble Aβ
species while using the same techniques.
Two studies have reported the comparative toxicities
of different soluble Aβ oligomer species by using LDH
(lactate dehydrogenase release) and MTT (oxidoreduc-
tase activity) cell viability assays. Deshpande and col-
leagues [45] examined the relative toxicities of purified
spherical Aβ(1-42) oligomers [50], ADDLs [132], and fi-
brils [50]. However, because solutions of soluble Aβ olig-
omers in the neurobasal medium used in this study have
been shown to change with time [19], it is not possible
to draw definitive structure-activity conclusions from
the results of this study. In the second study, Ono and
colleagues [133] reported relative toxicities of purified,
cross-linked Aβ(1-40) dimers, trimers, and tetramers,
which were shown to be relatively stable under the assay
conditions. In an MTT assay, half maximal effective con-
centration values were 67.3, 41.6, 24.5, 20.5, and 57.6
μM, respectively, for monomer, dimer, trimer, tetramer,
and fibrils. Comparable toxicity was obtained in an LDH
assay. The micromolar concentrations of Aβ species used
in this study were approximately six orders of magnitude
greater than in vivo Aβ concentrations, and the relevance
of cell culture MTT-type assays to the in vivo synaptotoxi-
city of Aβ species has been questioned [134]. Therefore,
the results of the study by Ono and colleagues provide lit-
tle understanding of the relative in vivo toxicities of sol-
uble Aβ species.
More recently, cognitive effects in vivo were assessed
in rats by using the alternating lever cyclic ratio assay
following intracerebroventricular (ICV) injections of
cell- and synthetically derived soluble Aβ oligomers [33].
Monomer and low-n-mer soluble Aβ oligomers derived
from 7PA2 cells [29,135-137], trimer and a dodecameric
species (Aβ*56) extracted from Tg2576 mouse brain
[37], and synthetic soluble Aβ oligomers (ADDLs) [43]
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media from 7PA2 cells caused significant cognitive defi-
cits. Evaluation of size exclusion chromatography (SEC)-
enriched dimer or trimer fractions of 7PA2 cell-conditioned
media showed significant cognitive deficits following injec-
tion of dimer-enriched fractions but a non-significant effect
upon injection of trimer-enriched fractions. SEC-purified
monomer had no effect. Aβmonomer was the predominant
Aβ species in unfractionated 7PA2 conditioned media, and
the amounts of dimer and trimer injected in the dimer- and
trimer-enriched fractions were considerably greater than
the amounts injected in unfractionated conditioned media.
However, cognitive effects following injection of unfractio-
nated conditioned media were comparable to or exceeded
the observed effects following treatment with dimer- and
trimer-enriched fractions. Thus, there is an inherent ambi-
guity regarding the results reported for 7PA2-derived Aβ
species that is difficult to explain. One possible explan-
ation is that a higher-order soluble Aβ oligomer species
contributes to the cognitive deficits observed upon injec-
tion of unfractionated 7PA2 conditioned media and is a
more potent inhibitor of cognitive function than Aβ dimer
or trimer species or both. Another possible explanation is
that combinations of different soluble Aβ oligomer species,
perhaps interacting differently with different neuronal re-
ceptors, have an additive or synergistic toxicological effect.
Trimers extracted from aged Tg2576 mouse brain also
failed to elicit significant cognitive deficits. However, con-
sistent with other in vivo efficacy studies [37], a dodeca-
meric soluble Aβ oligomer extracted from aged Tg2576
mouse brain (Aβ*56) caused significant cognitive deficits.
Synthetic soluble Aβ oligomers (ADDLs) also caused cogni-
tive deficits following ICV injection. The results of this
study show that ICV injection of soluble Aβ oligomers
from different sources causes cognitive deficits in wild-type
rats and that these deficits are reversible. The results of the
study show that soluble Aβ oligomer containing condi-
tioned media of 7PA2 cells is more potent than solutions of
Aβ*56 obtained from aged Tg2576 mouse brains or solu-
tions of synthetically prepared soluble Aβ oligomers
(ADDLs). However, because it is not possible to quantita-
tively characterize the exact nature or distribution of soluble
Aβ species in these different preparations, it is not possible
to draw definitive conclusions from this study regarding the
structure-activity relationships between individual soluble Aβ
oligomer species.
In a more recent study, Moreth and colleagues [19] pre-
pared, characterized, and evaluated the hippocampal bind-
ing and effects on neurotransmission of spheroidal,
protofibrillar, and fibrillar Aβ aggregates. Under the condi-
tions used to test for hippocampal binding and neuro-
transmission, the different species where shown to be
relatively unchanged. Monomeric and fibrillar Aβ did not
bind to mature hippocampal neurons (DIV21) or effectneurotransmission at concentrations as high as 1 μM. In
contrast, spheroidal and protofibrillar Aβ aggregates dis-
played punctate binding to mature hippocampal neurons
and impaired neurotransmission with nanomolar potency.
Significantly, the mode of impairment of neurotransmis-
sion was different for spheroidal Aβ aggregates, which im-
paired LTP at 30 nM, compared with protofibrillar
aggregates, which impaired basal neurotransmission at
100 nM. Spheroidal Aβ aggregates had no effect on basal
neurotransmission at concentrations as high as 100 nM.
Although this study was unable to address the compara-
tive neurotoxicity of discrete soluble Aβ oligomers, it did
show that different forms of soluble Aβ oligomers can
trigger distinct neuronal activities.
At this point, the exact structures of the toxicologically
relevant soluble Aβ oligomer species have not been deter-
mined to the complete exclusion of other possible struc-
tures, and analytical tools do not exist to characterize the
Aβ oligomers that form at concentrations in the AD brain
[44,138]. The numerous studies reporting neuronal tox-
icity for different soluble Aβ oligomers support the con-
clusion that multiple soluble Aβ oligomer species exhibit
neuronal toxicity, rather than a single, discrete toxic spe-
cies. This suggestion of multiple toxic soluble Aβ oligomer
species may also explain the plethora of reported neuronal
receptors that mediate the effects of soluble Aβ oligomers
(Table 1) [139-165], a discussion of which is well beyond
the scope of this review. (See the perspective of Benilova
and De Strooper [166] for a good introduction to this
complex and controversial field of study.)
Despite recognition that soluble Aβ oligomers are key
structures causing AD memory malfunction and cognitive
deficits, drug discovery efforts targeting these species have
been hampered by perceived technical difficulties of gener-
ating physiologically relevant preparations of synthetic sol-
uble Aβ oligomers and by differing terminologies and
methodologies used by various researchers [167]. However,
well-characterized and documented preparations of syn-
thetic soluble Aβ oligomers have been reported by numer-
ous researchers [19,40,43,95,100,107,108,111,168-170] that
generate soluble Aβ oligomers with little or no detectable fi-
brillar Aβ species. With the availability of a number of well-
documented preparations of different soluble Aβ oligomer
species and tools for comparative characterization, it is
hoped that additional side-by-side testing of various soluble
Aβ oligomer preparations in different toxicity paradigms
such as reversal of basal neurotransmission, LTP inhibition,
changes in AMPA receptor trafficking, tau phosphorylation,
and loss of dendritic spines [19,108,109,170] will be con-
ducted and reported.
Amyloid-beta immunotherapies in development
Successful immunotherapies developed for most diseases
rely upon antibodies that possess high selectivity for a
Table 1 Reported receptors that bind or mediate the toxicity of soluble amyloid-beta oligomers
Reported receptor
Amylin receptor [139] NMDA receptor [140-144] Sortilin [145]
P53-Bax cell death pathway [146] cAMP/PKA/CREB-signaling pathway [147,148] Tau protein kinase 1/glycogen synthase kinase-3β [51]
c-Jun N-terminal kinase [149] α-synuclein [150] P/Q-type calcium currents [49]
Cyclin-dependent kinase 5 [149] EphB2 [151] Dynamin and RhoA [152]
mGluR, mGluR5, mGluR2 [108,142,149,153,154] TNFα [155] Cofilin [140]
p38 mitogen-activated protein kinase [149] PrPc [154,156-159] Calcineurin [160-162]
α 7-nicotinic receptors [105] AMPA [160] Brain-derived neurotrophic factor [131]
Human LilrB2 [163] Insulin receptor [164] Sigma 2 receptor [165]
STI1 [156]
NMDA, N-methyl-D-aspartate; TNFα, tumor necrosis factor alpha.
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ever, all Aβ-directed immunotherapies currently in clin-
ical development are based on non-selective antibodies
that bind multiple Aβ species. Treatment with non-
selective anti-Aβ antibodies that bind monomeric or
oligomeric Aβ (or both) potentially could succeed in a
prodromal treatment paradigm by reducing total brain
Aβ to levels below the toxicological threshold. However,
given the high concentrations of monomeric and fibrillar
Aβ compared with soluble Aβ oligomers in the AD brain
[57-65] and the low levels of antibodies that penetrate
the brain from the periphery [171], it will be very chal-
lenging for non-selective anti-Aβ antibodies that bind
monomeric or fibrillar Aβ (or both) to show efficacy
when administered to patients with mild cognitive im-
pairment or mild-to-moderate AD. In contrast, the acute
synaptic toxicity and very low brain levels of soluble Aβ
oligomers suggest that anti-Aβ antibodies with selective
affinity for soluble Aβ oligomers could provide thera-
peutic benefit for patients with mild cognitive impair-
ment or mild-to-moderate AD.
It might seem difficult to generate a monoclonal anti-
body that does not bind monomeric or fibrillar Aβ yet
possesses high affinity for structurally heterogeneous sol-
uble Aβ oligomers. However, monomeric, oligomeric, and
fibrillar Aβ species have been reported to have distinct
conformational characteristics [172-175]. Moreover, anti-
bodies with selective affinity for soluble Aβ oligomers ver-
sus monomeric and fibrillar Aβ have been reported
[9,176,177]. These several examples of antibodies suggest
that therapeutically relevant soluble Aβ oligomer-directed
antibodies are indeed feasible.
A number of recent publications have reviewed Aβ
immunotherapies currently in clinical trials, with an em-
phasis on the efficacy of the drugs for treating AD
[178-187], and the clinical results will not be presented
in this review, with the exception of an analysis of the
brain levels of solanezumab and bapineuzumab in re-
cently reported clinical trials. Instead, this review willfocus on a discussion of the comparative affinities of the
Aβ antibodies in clinical development for monomeric,
soluble oligomeric, and fibrillar Aβ species. Notably,
none of the Aβ immunotherapies currently in clinical
development selectively targets soluble Aβ oligomers, as
discussed below and summarized in Table 2.
Solanezumab
Solanezumab is unique among Aβ antibodies currently
in clinical development because it does not bind fibrillar
Aβ. Solanezumab is a humanized, IgG1 monoclonal anti-
body derived from the murine monoclonal antibody,
266. 266 was selected for its high-affinity binding to sol-
uble Aβ, although the exact nature of the soluble Aβ it
binds was not reported. It has been suggested that 266 is
a conformation-specific antibody that solely recognizes
soluble Aβ and readily binds monomeric Aβ [188-190],
without binding APP or the C-terminal APP cleavage
product of α-secretase [189]. It has been reported that 266
selectively sequesters Aβ monomer and dimer in the per-
iphery of 3-month-old APP transgenic mice [190], and de-
finitive evidence for 266 binding of monomeric Aβ has
been reported [191]. A study using crossed-linked soluble
Aβ oligomers showed 266 could immunoprecipate Aβ
monomer and low-molecular-weight dimer, trimer, and
possibly tetramer [192]. A study involving a competitive
ELISA showed that 266 had a seven-fold higher affinity
for monomeric Aβ than synthetic soluble Aβ oligomers
[193]. Several studies have shown that 266 does not bind
Aβ plaques or vascular amyloid [188,190,194]. Thus, ac-
cording to the available data, solanezumab and 266 bind
monomeric and lower-molecular-weight soluble Aβ oligo-
mer species, with a preference for monomeric Aβ, but do
not bind fibrillar Aβ species.
Clinical trial pharmacokinetic data for brain levels of sola-
nezumab have not been reported. However, target engagement
data reported for the phase 2, multiple ascending-dose
clinical trials (Table 3) [183] provide a possible under-
standing of the lack of efficacy of solanezumab in clinical
Table 2 Comparison of binding affinities of amyloid-beta
(Aβ) immunotherapies in development for Aβ monomer,
soluble Aβ oligomers, and fibrillar Aβ
Binding affinitya
Aβ antibody Aβ monomer Aβ oligomers Aβ plaque
Solanezumab/266 +++ ++ −
Bapineuzumab/3D6 ++ +++ +++
Crenezumab ++ +++ ++
Ponezumab/D-2H6 ++ ++ +++
BiiB037/NI-101.11 + +++ +++
BAN2401/mAb158 − +++ +++
Gantenerumab + ++ +++
SAR228810/13C3 − +++ +++
aBased on published patent applications or peer-reviewed scientific publications.
+, low affinity binding; ++, moderate affinity binding; +++, high affinity binding;
−, very low affinity or no binding.
Goure et al. Alzheimer's Research & Therapy Page 7 of 152014, 6:42
http://alzres.com/content/6/4/42trials [186]. The data for the 400 mg/month and 400 mg/
week dose levels show approximately a 2.7-fold increase
in solanezumab bound Aβ at the higher dose level (5,858
versus 15,825 pg/mL total Aβ40 and Aβ42) [183], showing
that there was incomplete target engagement at the 400
mg/month dose level used in the pivotal phase 3 trials.
Solanezumab binds Aβ monomer with higher affinity than
soluble Aβ oligomers and does not bind or disaggregate fi-
brillar Aβ. Because incomplete target engagement oc-
curred at the dose level used in the phase 3 trials, it is
unlikely any solanezumab was available to bind soluble Aβ
oligomers; thus, the lack of efficacy of solanezumab at the
dose levels used in the phase 3 clinical trials is not
unexpected.
Bapineuzumab
Bapineuzumab is a humanized, IgG1 monoclonal anti-
body derived from the murine antibody, 3D6. Bapineu-
zumab and 3D6 are non-selective Aβ antibodies that
bind with high affinity to monomeric Aβ [192], soluble
Aβ oligomers [170], and fibrillar Aβ [195-197] but do
not recognize APP or the product of β-secretaseTable 3 Mean cerebrospinal fluid levels of bound and
unbound amyloid-beta (Aβ)40 and Aβ42 in Alzheimer’s
disease patients treated with solanezumab




100 mg Q4W 625 0.0
100 mg QW 3,750 275
400 mg Q4W 5,625 233
400 mg QW 15,000 825
aSolanezumab phase 2 MAD data [183]. bMean pg/mL levels of total bound
and unbound Aβ40 and Aβ42 in cerebrospinal fluid (CSF) of treated patients,
derived from Figures 3A and 3B reported by Farlow and colleagues [183].
Q4W, monthly dosing; QW, weekly dosing.cleavage of APP [198]. In a competitive ELISA assay study,
3D6 was found to bind monomeric Aβ and synthetic sol-
uble Aβ oligomers with similar affinity [193]. Babineuzu-
mab/3D6 bind vascular amyloid and Aβ plaques in
hAPP transgenic mice brains and human AD brains
and clear vascular amyloid and Aβ plaques in hAPP
transgenic mice brains [188,197,199-201]. Thus, bapi-
neuzumab and 3D6 do not distinguish between the
various Aβ species in the AD brain.
Mean CSF levels of bapineuzumab reported in the
phase 2, multiple ascending-dose pharmacokinetic clin-
ical studies were 4.9, 18.1, 27.2, and 44.7 ng/mL, respect-
ively, at dose levels of 0.15, 0.5, 1.0, and 2 mg/kg (six
infusions, 13 weeks apart) [202], which upon conversion
to molar concentrations are 0.03, 0.12, 0.18, and 0.3
pmol/mL, respectively, based on a bapineuzumab mo-
lecular weight of 150 kDa. In the same studies, placebo-
treated mean CSF levels of Aβ(1-42), Aβ(x-42), and
Aβ(1-40) were 376.7, 537.9, and 6,705.4 pg/mL, respect-
ively, which upon conversion to molar concentrations
are 0.08, 0.12, and 1.55 pmol/mL, respectively (assuming
the molecular weight of Aβ(x-42) is the same as that of
Aβ(1-40)). The highest bapineuzumab dose level in
phase 3 pivotal trials was 1 mg/kg (six infusions, once
every 13 weeks) [187]. Thus, the total mean Aβ CSF
levels were approximately an order of magnitude greater
than mean levels of bapineuzumab. Because bapineuzu-
mab binds monomeric Aβ with similar affinity to soluble
Aβ oligomers and fibrillar Aβ and because Aβ soluble
oligomer levels are orders of magnitude less than Aβ
monomer and fibrils levels in the AD brain [58-65], it is
clear that bapineuzumab was not dosed high enough in
the pivotal phase 3 trials to effectively sequester soluble
Aβ oligomers. Thus, the absence of efficacy of bapineu-
zumab in clinical trials is not unexpected.
Crenezumab
Crenezumab (MABT5102A or MABT) is a humanized,
IgG4 monoclonal anti-Aβ antibody that was engineered
to reduce Fcγ receptor-mediated microglia activation
and minimize adverse effects due to vasogenic edema
and cerebral microhemorrhage [203,204]. Crenezumab
binds Aβ monomer, soluble Aβ oligomers, and fibrillar
Aβ with similar affinities and binds plaques in hAPP
transgenic mice and human AD brain tissues [203,204].
Similar binding of crenezumab to human Aβ(1-40) and
Aβ(1-42) peptides and mouse/rat Aβ(1-42) has also been
reported [204]. These results indicate that crenezumab
does not possess selectivity for different Aβ species
[204]. Consistent with a lack of selectivity, crenezumab
prevents Aβ aggregation and disaggregates pre-aggregated
Aβ species. Thus, crenezumab is similar to bapineuzumab
with respect to non-selective binding of monomeric, olig-
omeric, and fibrillar Aβ species.
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Ponezumab is a humanized, modified IgG2 monoclonal
antibody derived from the murine monoclonal antibody,
2H6. This progenitor murine antibody binds to mono-
meric Aβ(1-40) with high affinity but does not bind to
Aβ(1-16), Aβ(1-28), Aβ(1-38), Aβ(1-42), or Aβ(1-43)
[205]. Intracranial injection of 2H6 and its deglycosyl-
ated form into plaque-rich, 20-month-old Tg2576 mice
followed by histological analysis of total Aβ load in the
hippocampus and frontal cortex showed significant
plaque reduction in both regions compared with control
tissues [206], suggesting that these antibodies bind and
disaggregate fibrillar amyloid. More recent studies show
that ponezumab labels amyloid plaques in 14-month-old
Tg2576 mouse and human AD brains [207], demonstrat-
ing binding to fibrillar Aβ. Binding of ponezumab to
Tg2576 mouse brain plaque was comparable to the
known high-affinity binding of the N-terminal Aβ anti-
body 6E10. Ponezumab was also reported to bind mono-
meric, oligomeric, and fibrillar forms of Aβ(1-40) but
did not show appreciable binding to monomeric, oligo-
meric, or fibrillar forms of Aβ(1-42) [207]. Thus, al-
though ponezumab displays selectivity for Aβ(1-40)
versus other Aβ peptide isoforms, it is relatively non-
selective for monomeric, soluble oligomeric, or fibrillar
Aβ species.
BiiB037
BiiB037 is a human IgG1 monoclonal antibody derived
from a patient with AD by using reverse translational
medicine methodology [208]. In vitro BiiB037 binds fi-
brillar Aβ(1-42) with high affinity but does not bind sol-
uble Aβ(1-40) [209]. Although explicit details of the
binding characteristics of BiiB037 have not been publicly
disclosed, results reported by Dunstan and colleagues
[209] and data in the patent covering BiiB037 [208] sug-
gest that BiiB037 is very similar, or identical, to antibody
NI-101.11, which binds with high affinity to Aβ plaques
in human AD brain tissue samples [208]. Such binding
is not blocked by monomeric Aβ(1-16) or Aβ(1-42),
showing selective affinity for fibrillar Aβ versus Aβ
monomers [208]. Comparison of binding affinity in an
Aβ plate-based ELISA showed greater than 100-fold-
higher affinity for fibrillar Aβ(1-42) than for monomeric
Aβ(1-42) [208]. SEC studies showed that NI-101.11
bound to fluorescein isothiocyanate-labeled Aβ(1-42) in
the early-eluting peak (non-retained, large Aβ species)
but that little binding was associated with the retained,
low-molecular-weight Aβ peak [208]. Many researchers
have deployed SEC to separate higher-molecular-weight
soluble Aβ oligomer species from low-molecular-weight
Aβ species [20,44,130,155,210-212], and in all cases the
higher-molecular-weight, early-eluting peak contains sol-
uble Aβ oligomers or Aβ protofibrils or both. Togetherthese results show that NI-101.11 binds soluble Aβ olig-
omers and protofibrils in addition to fibrillar Aβ. Con-
sistent with this conclusion is the finding that NI-101.11
inhibits the formation of Aβ fibrils in vitro [208]. Thus,
according to the available data, BiiB037/NI-101.11 binds
soluble Aβ oligomers and fibrillar Aβ with high affinity
and binds monomeric Aβ with low affinity.
BAN2401
BAN2401 is a humanized, IgG2a monoclonal antibody
derived from the murine precursor mAb158, which was
raised against Aβ protofibrils generated from Aβ(1-42)-
E22G, the arctic mutant of the Aβ peptide [210]. Al-
though mAb158 is claimed to be a ‘highly protofibril-
selective monoclonal antibody’ [213], published data
show that it binds fibrillar Aβ with a high affinity similar
to that of protofibrils in a dot-blot assay [210,214] and
binds fibrillar deposits in transgenic APP-ArcSwe mice
brain (see Figure S2 in [213]). In a more recent study,
mAb158 was shown to bind soluble Aβ oligomer frac-
tions in the molecular weight range of 80 to 2,000 kDa
under conditions in which protofibrillar species were not
detected [119]. In this study, mAb158 showed essentially
no binding to low-molecular-weight Aβ oligomeric spe-
cies in the molecular weight range of 5 to 80 kDa. A lack
of binding to low-molecular-weight Aβ species - mono-
meric to tetrameric Aβ(1-40), Aβ(1-16), and Aβ(17-40) -
was found in an earlier study [213]. Thus, mAb158 binds
higher-molecular-weight Aβ aggregates, including soluble
Aβ oligomers, protofibrils, and fibrillar Aβ. Consistent
with the binding of mAb158 to fibrillar Aβ, intracranial in-
jection of mAβ158 in a transgenic APP-Swe mouse model
was reported to cause a significant reduction in plaque
burden by 72 hours after injection [214]. In a subsequent
study in a transgenic APP-ArcSwe mouse model [213], 4
months of weekly intraperitoneal injections of mAb158 to
9- to 10-month-old mice with modest plaque burden re-
sulted in a significant reduction of Aβ protofibrils (74%)
but no significant reduction in total soluble or insoluble
Aβ levels in the cerebral cortex or hippocampus as deter-
mined by immunohistochemical analysis. The differences
in effects of mAb158 on existing plaque burden in these
two studies may be due to different administration routes
(direct intracranial versus peripheral injections). As noted
by Lord and colleagues [213], it may also be attributable
to the APP-ArcSwe mouse model used in the more recent
study, a model that exhibits more highly insoluble dense-
core plaques, preventable only by early and continuous
Aβ immunotherapy. Thus, mAb158/BAN2401 binds
higher-molecular-weight soluble Aβ oligomers (referred
to as protofibrils in the mAb158 literature) and fibrillar
Aβ with high affinity and has low affinity for binding
monomeric Aβ and lower-molecular-weight soluble Aβ
oligomers.
Goure et al. Alzheimer's Research & Therapy Page 9 of 152014, 6:42
http://alzres.com/content/6/4/42Gantenerumab
Gantenerumab is a humanized monoclonal antibody that
was optimized to have high-affinity binding of fibrillar Aβ
and shows high-affinity binding to diffuse and dense-core
plaques in human AD brain and APP transgenic mouse
brain tissues [215]. Gantenerumab also binds soluble Aβ
oligomers with high affinity and, to a lesser extent, Aβ
monomer. The reported binding constants (Kds) for gan-
tenerumab binding to fibrillar Aβ, soluble Aβ oligomers,
and Aβ monomer are 0.6, 1.2, and 17 nM, respectively
[215]. The dissociation constants (kds) for gantenerumab-
Aβ complexes were reported to be 2.8 × 10−4, 4.9 × 10−4,
and 1.2 × 10−2, respectively, for fibrillar Aβ, Aβ oligomers,
and Aβ monomer [215], suggesting a more rapid exchange
of antibody-monomer complex compared with antibody-
fibril or oligomer complexes. The selective affinity of gan-
tenerumab for fibrillar Aβ and soluble Aβ oligomers sug-
gests that it may be similar to BiiB013/NI-101.11 and
BAN2401/mAb158. Consistent with its high-affinity bind-
ing to fibrillar Aβ, gantenerumab caused a significant,
dose-dependent reduction in amyloid plaques in human
AD brain tissue [215]. Immunohistochemical analysis of
PS2APP transgenic mice brain tissue 3 days after intraven-
ous injection of gantenerumab showed dose-dependent
binding to amyloid plaques. Significantly, pharmacokinetic
analysis in PS2APP transgenic mice following a single
intravenous bolus dose showed sustained binding of gan-
tenerumab to plaques in the brain for up to 9 weeks post-
dosing, even though there was no detectable antibody in
the plasma beyond 3 weeks post-dosing [215]. In a chronic
treatment study in 5- to 6-month-old PS2APP transgenic
mice, gantenerumab caused a significant reduction in pre-
existing small plaques; however, there was an increase in
larger plaques [215]. These results suggest that ganteneru-
mab causes a redistribution of Aβ from small plaques to
large plaques, possibly via disaggregation of smaller, less
mature plaques. Gantenerumab-mediated disaggregation of
existing plaques is consistent with the observations of vaso-
genic edema and microhemorrhage in human patients with
AD treated with gantenerumab in clinical trials [216]. Thus,
gantenerumab non-selectively binds soluble Aβ oligomers
and fibrillar Aβ with similar high affinity in comparison
with its lower-affinity binding of monomeric Aβ.
SAR228810
SAR228810 is a humanized, monoclonal antibody derived
from the murine monoclonal antibody 13C3, which was
raised to Aβ protofibrils derived from Aβ(1-42) [217,218].
The humanized antibody was engineered into an IgG4
framework to reduce binding to Fcγ and C1q receptors
and decrease risks of amyloid-related imaging abnormal-
ities [219]. Although specific binding characteristics of
SAR228810 have not been publicly disclosed, results re-
ported by Pradier and colleagues [219] and data in thepatent application claiming humanized variants of
13C3 [220] suggest that SAR228810 is very similar, or
identical, to antibody LP09027 [220]. Antibody 13C3
and its humanized variants are reported to bind with
higher affinity to SEC-separated protofibrillar Aβ(1-42)
than to low-molecular-weight Aβ(1-42) [217,218,220].
As noted previously, many researchers have used SEC
to separate higher-molecular-weight soluble Aβ oligo-
mer species from low-molecular-weight Aβ species
[20,44,130,155,210-212], and in all cases the higher-
molecular-weight, early-eluting peak contains soluble
Aβ oligomers or Aβ protofibrils or both. Moreover,
as reported by Hepler and colleagues [44], the lower-
molecular-weight, late-eluting peak contains predominately
monomeric Aβ. Thus, these data show that 13C3 and its
humanized variants selectively bind Aβ oligomers or proto-
fibrils (or both) compared with monomeric Aβ. In com-
petitive ELISA experiments, monomeric Aβ(1-28),
Aβ(1-16), or Aβ(25-35) does not prevent binding of hu-
manized 13C3 to plates coated with Aβ(1-42) [220].
Ravetch and Fukuyama [218] reported that 13C3 binds
only to the higher-molecular-weight Aβ species con-
tained in the supernatants from 7PA2 cells, in contrast
to the non-selective Aβ antibody 4G8 that binds low-,
medium-, and higher-molecular-weight Aβ species.
Collectively, these data show the selectivity of 13C3 for
higher-molecular-weight Aβ oligomers versus lower-
molecular-weight Aβ oligomers and monomer. Anti-
body 13C3 was shown to bind fibrillar Aβ(1-42) and
label Aβ deposits in human AD brain tissue samples
[218]. Antibody LP09027 was shown to bind fibrillar
Aβ in vitro and to label AB deposits in brain sections
from APP-PS1 mice [220]. Thus, the reported data sug-
gest that 13C3/SAR228810 is very similar to mAb158/
BAN2401 and binds higher-molecular-weight soluble
Aβ oligomers (referred to as protofibrils in the 13C3/
SAR228810 literature) and fibrillar Aβ with high affinity
and has low affinity for binding monomeric Aβ and
lower-molecular-weight soluble Aβ oligomers.
Conclusions
The lack of efficacy observed for Aβ immunotherapies
in clinical development is not unexpected given their
lack of selectivity for soluble Aβ oligomers compared
with monomeric or fibrillar Aβ and given the tremen-
dous quantities of monomeric or fibrillar Aβ in the AD
brain relative to soluble Aβ oligomers. Aβ antibodies op-
timized to bind soluble Aβ oligomers selectively are
much more likely to succeed in AD clinical trials and
should be aggressively pursued.
The prediction that immunotherapies targeting soluble
Aβ oligomers will elicit clinical benefit is supported by
studies of human Aβ autoantibodies, of which only a
subset appears to be disease-protective (in particular, the
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[221-223]. Thus, immunotherapeutics with high selectiv-
ity for soluble Aβ oligomers, which resemble these pro-
tective auto-antibodies, are expected to deliver a clinical
advantage compared with the non-selective immuno-
therapies in clinical development.
Studies have demonstrated that antibodies with select-
ive affinity for soluble Aβ oligomers can block soluble
Aβ oligomer-mediated synaptotoxicity in cell cultures
[108,224] and rapidly normalize memory deficits in
transgenic AD mouse models [176]. These findings sup-
port the concept that antibodies with selective affinity
for soluble Aβ oligomers may be a more effective thera-
peutic strategy than antibodies with high affinity for
monomeric or fibrillar Aβ or both.
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